Medicare limits coverage of controversial Alzheimer's drug to those in clinical trials
Headline from KVIA El Paso
By Tami Luhby, CNN Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.
KVIA El Paso's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Medicare coverage for a costly, but controversial, new Alzheimer's drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication.
Medicare on Thursday finalized its plan to restrict coverage for the controversial, pricey Alzheimer’s drug Aduhelm to patients participating in clinical trials.
By Tami Luhby, CNN Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services announced Thursday.
Medicare officials announced on Thursday that the health insurance program for older Americans will sharply limit coverage of a costly and controversial new Alzheimer's drug.
The U.S. government health plan for people age 65 and over on Thursday issued its final coverage policy for Biogen Inc’s Alzheimer’s drug, Aduhelm, moving forward with an unusually strict
Medicare announced Thursday that it will limit its coverage of the pricey new drug Aduhelm to Alzheimer's patients enrolled in clinical trials of the drug.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Medicare limits coverage of controversial Alzheimer's drug to those in clinical trials | Since Then
